Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | AGPAT2 | O15120 | 2/20 | 0.41 |
| ▸ | CALCA | P06881 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20339039 | 0.84 | CYP1A2 (0.49) | CYP1A2CYP2D6RAB9AMAPTNPC1 | |
| SCHEMBL20340282 | 0.80 | RAB9A (0.44) | CYP1A2CYP2D6RAB9AMAPTNPC1 | |
| SCHEMBL20338993 | 0.78 | HRH4 (0.42) | CYP1A2CYP2D6RAB9AMAPTNPC1 | |
| SCHEMBL21530398 | 0.77 | NPC1 (0.60) | RAB9AMAPTNPC1MEN1KMT2A | |
| SCHEMBL20340704 | 0.76 | ROCK2 (0.46) | CYP1A2CYP2D6RAB9AMAPTNPC1 | |
| SCHEMBL20339000 | 0.76 | CYP1A2 (0.50) | CYP1A2CYP2D6RAB9AMAPTNPC1 | |
| SCHEMBL20338986 | 0.75 | NPC1 (0.54) | CYP1A2RAB9AMAPTNPC1POLB | |
| SCHEMBL20340277 | 0.75 | MEN1 (0.46) | CYP1A2CYP2D6RAB9AMAPTNPC1 | |
| SCHEMBL20355109 | 0.75 | MCHR1 (0.52) | CYP1A2CYP2D6RAB9ANPC1CYP3A4 | |
| SCHEMBL2410497 | 0.75 | RAB9A (0.62) | CYP1A2CYP2D6RAB9AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739072-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2023-08-29 | — | — | US | disclosed |
| US-11739072-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2023-08-29 | — | — | US | disclosed |
| US-11739072-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2023-08-29 | — | — | US | disclosed |
| US-20220135535-A1 | HETEROARYL COMPOUNDS AND THEIR USE | MINORYX THERAPEUTICS S.L. (ES) | 2022-05-05 | — | — | US | disclosed |
| US-20220135535-A1 | HETEROARYL COMPOUNDS AND THEIR USE | MINORYX THERAPEUTICS S.L. (ES) | 2022-05-05 | — | — | US | disclosed |
| EP-3562811-B1 | HETEROARYL COMPOUNDS AND THEIR USE | MINORYX THERAPEUTICS S L (ES) | 2022-03-16 | — | — | EP | disclosed |
| US-11174242-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2021-11-16 | — | — | US | disclosed |
| US-11174242-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2021-11-16 | — | — | US | disclosed |
| US-20190337922-A1 | HETEROARYL COMPOUNDS AND THEIR USE | MINORYX THERAPEUTICS S.L. (ES) | 2019-11-07 | — | — | US | disclosed |
| EP-3562811-A1 | HETEROARYL COMPOUNDS AND THEIR USE | Minoryx Therapeutics S.L. (ES) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018122775-A1 | HETEROARYL COMPOUNDS AND THEIR USE | MINORYX THERAPEUTICS S.L. (ES) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135535-A1 | HETEROARYL COMPOUNDS AND THEIR USE | GBA1, GBA2, GAA | CYP1A2 815/4885CYP2D6 892/4885RAB9A 83/4885 |
| US-20190337922-A1 | HETEROARYL COMPOUNDS AND THEIR USE | GBA1, GBA2, GAA | CYP1A2 815/4885CYP2D6 892/4885RAB9A 83/4885 |
| US-11174242-B2 | Heteroaryl compounds and their use | GBA1, GBA2, GAA | CYP1A2 815/4885CYP2D6 892/4885RAB9A 83/4885 |
| US-11739072-B2 | Heteroaryl compounds and their use | GBA1, GBA2, GAA | CYP1A2 815/4885CYP2D6 892/4885RAB9A 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.